🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. Nadroparin, long term

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 3 small molecule active

    1 trial

  2. Nalfurafine Hydrochloride

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Uremic Pruritus

    phase 3 small molecule active

    1 trial

  3. Namodenoson

    Can-Fite BioPharma

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  4. Nano-crystalline Megestrol Acetate Oral Suspension

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  5. Napabucasin, Bendatax 6 mg/ ml, Bendacitabin 38 mg/ml Pulver zur Herstellung einer Infusionslösung

    The George Institute

    Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.

    phase 3 small molecule active

    1 trial

  6. Nemolizumab

    Galderma Australia Pty Ltd

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  7. Nemolizumab

    Galderma Australia Pty Ltd

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  8. Neofordex 40 mg tablets, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., PREDNISONE

    Pari Pharma GmbH

    Adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations

    phase 3 small molecule active

    1 trial

  9. Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Imnovid 2 mg hard capsules, Privigen 100 mg/ml solution for infusion, ELRANATAMAB, Imnovid 3 mg hard capsules

    Pfizer Australia Pty Ltd

    MULTIPLE MYELOMA

    phase 3 small molecule active

    1 trial

  10. Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    4 trials

  11. Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, avalglucosidase alfa, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Glycogen storage disease type II

    phase 3 small molecule active

    1 trial

  12. Niclosamide

    United Therapeutics Europe Ltd

    Covid19

    phase 3 small molecule completed

    1 trial

  13. Nicotine patch

    Jasper Therapeutics

    Nicotine Dependence

    phase 3 small molecule active

    1 trial

  14. Nicotine polacrilex, Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 3 small molecule completed

    1 trial

  15. Nicotinomide

    United Therapeutics Europe Ltd

    Glaucoma, Open-Angle

    phase 3 small molecule active

    1 trial

  16. Nilemdo 180 mg film-coated tablets, Obicetrapib, Obicetrapib matching placebo, Bempedoic acid matching placebo

    A.Menarini Australia Pty Limited

    Dyslipidemia at High to Very High Cardiovascular Risk

    phase 3 small molecule active

    1 trial

  17. Nilotinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Myeloid Leukemia, Chronic Phase

    phase 3 small molecule active

    1 trial

  18. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and s

    Sanofi Pasteur

    Healthy volunteers (Meningococcal infection)

    phase 3 small molecule active

    1 trial

  19. Niraparib - capsule - 100 mg, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for ABIRATERONE ACETATE, -, Niraparib, PREDNISOLONE , ABIRATERONE , Placebo for Niraparib, Abiraterone acetate - tablet - 250 mg, Placebo for NIRAPARIB / ABIRATERONE ACETATE 50/500 mg FDC, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Prednison acis 5 mg, Tabletten, Placebo for NIRAPARIB / ABIRATERONE

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  20. Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  21. Nivolumab

    Bristol-Myers Squibb

    Bladder Cancer

    phase 3 mab completed

    1 trial

  22. Nivolumab

    Nektar Therapeutics UK Limited

    Bladder Cancer

    phase 3 mab completed

    1 trial

  23. Nomlabofusp, Placebo to Nomlabofusp

    Larimar Therapeutics

    Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.

    phase 3 small molecule active

    1 trial

  24. NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection, Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ADVATE 1 500 IU/2 ml powder and solvent for solution for injection, Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ELOCTA 500 IU Powder and solvent for solution for injection, ELOCTA 750 IU Powder and solvent for solution for injection, ELOCTA 2000 IU Powder and solvent for

    Hoffmann-La Roche

    Type 3 Von Willebrand Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources